In brief: Biodiem; Avexa
Tuesday, 11 January, 2005
BioDiem (ASX:BDM) has received a US$1m signing-on payment, the first in a number of milestone payments due under its US$8m licence agreement with Akzo Nobel's Nobilon.
Avexa antibacterial studies confirmed
Maryland-based company ImQuest BioSciences has confirmed the activity of Avexa's (ASX: AVX) antibacterial compounds against vancomycin-resistant enterococci (VRE).
Avexa aims to have a lead compound in proof-of-concept models by the end of 2005.
The microbiome helps to fight melanoma
Molecules produced by gut bacteria upon digestion of dietary fibre can improve the function of...
Heart implant brings hope to refractory angina patients
The coronary sinus reducer is understood to redistribute blood flow within the wall of the heart,...
Researchers genetically engineer snake antivenom
An international team of researchers has used genetic engineering to create so-called...
